Mocravimod is under clinical development by Priothera and currently in Phase III for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase III drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Mocravimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Mocravimod overview

KRP-203 is under development for the treatment of the autoimmune diseases like ulcerative colitis, subacute cutaneous lupus erythematosus, Acute Myeloid Leukemia (AML), secondary acute myeloid leukemia and Crohn’s disease and hematopoietic stem cell transplantation. The drug candidate is an orally administered immunosuppressant that acts by targeting S1P receptor. It was also under development for the treatment of the subacute cutaneous lupus erythematosus and ulcerative colitis and also for inflammatory bowel disease in Japan.

It was under development for the treatment of autoimmune diseases, inflammatory bowel disease, graft versus host disease (transplantation) and Crohn's disease. 

Priothera overview

Priothera is a clinical stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. Priothera is headquartered in Dublin, Ireland.

For a complete picture of Mocravimod’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.